Vietnam Investment Review

Imexpharm’s EBITDA margin rises to 22.3 per cent driven by cost management and growth

In September 2025, Imexpharm’s profit before tax surged by 101 per cent, while EBITDA increased by 48 per cent.
Professional Builder

Valued Sponsors of the National Housing Quality Award

Industry-leading individuals and companies join the mission to recognize and affect operational excellence in home building ...